Efficacy and safety of tolvaptan in patients with malignant ascites: a phase 2, multicenter, open-label, dose-escalation study.

导出 OA

翻译打印收藏纠错

作者： Toshihiro,Kudo ^[1] ; Yoshiyuki,Murai ^[2] ; Yoshitsugu,Kojima ^[3] ; Kenji,Uehara ^[3] ; Taroh,Satoh ^[4]

作者单位： Department of Frontier Science for Cancer and Chemotherapy, Graduate School of Medicine, Osaka University, Osaka, Japan. ^[1] Department of Medical Oncology, Osaka International Cancer Institute, Osaka Prefectural Hospital Organization, Osaka, Japan. ^[2] Headquarters of Clinical Development, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan. ^[3] Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan. ^[4]

关键词 ascitic fluid carcinoma malignant ascites safety tolvaptan

主题词老年人(Aged);腹水(Ascites);体重(Body Weight);女(雌)性(Female);人类(Humans);男(雄)性(Male);治疗结果(Treatment Outcome)

DOI 10.1093/jjco/hyaa196

PMID 33173939

发布时间 2021-03-25

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交